# Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

> **NCT06613685** · PHASE2,PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 73 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** lepetegravir
- **DRUG:** lenacapavir pacfosacil
- **DRUG:** Bictegravir/emtricitabine/tenofovir alafenamide
- **DRUG:** lepetegravir/lenacapavir pacfosacil FDC
- **DRUG:** Placebo to Match BVY
- **DRUG:** Placebo to Match GS1720/GS-4182 FDC

## Key facts

- **NCT ID:** NCT06613685
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-21
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study.
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613685, "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06613685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*